Research Analysts’ Recent Ratings Updates for CeriBell (CBLL)

Several analysts have recently updated their ratings and price targets for CeriBell (NASDAQ: CBLL):

• 9/3/2026 – CeriBell had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $29.00 price target on the stock.
• 8/28/2026 – CeriBell was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/18/2026 – CeriBell was upgraded by Barclays PLC to “neutral”.
• 8/18/2026 – CeriBell had its price target raised by BTIG Research from $28.00 to $30.00. They now have a “buy” rating on the stock.
• 8/13/2026 – CeriBell was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/11/2026 – CeriBell had its price target raised by Canaccord Genuity Group Inc. from $25.00 to $26.00. They now have a “buy” rating on the stock.
• 8/11/2026 – CeriBell had its “buy” rating reaffirmed by BTIG Research. They now have a $28.00 price target on the stock.
• 7/14/2026 – CeriBell was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Activity

In related news, CRO Joseph S. Manni sold 1,361 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $24.02, for a total value of $32,691.22. Following the completion of the sale, the executive directly owned 55,956 shares in the company, valued at $1,344,063.12. The trade was a 2.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Xingjuan Chao sold 6,068 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $145,753.36. Following the completion of the sale, the chief executive officer directly owned 781,731 shares of the company’s stock, valued at approximately $18,777,178.62. The trade was a 0.77% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 382,067 shares of company stock valued at $8,025,866. 17.70% of the stock is owned by corporate insiders.

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.